ZK-261991

Cat. No.: HY-15333: FAQs
Data Sheet Handling Instructions

Molarity Calculator

ZK-261991 is an orally active VEGFR tyrosine kinase inhibitor with an IC₅₀ of 5 nM for VEGFR2.

For research use only. We do not sell to patients.

ZK-261991 Chemical Structure

CAS No. : 886563-25-3

Size		Stock
MOQ		Minimum order quantity
50 mg		Get quote
100 mg		Get quote
250 mg		Get quote
Other size		Get quote

Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All VEGFR Isoform Specific Products:

View All Isoforms

VEGFR1/Flt-1 VEGFR2/KDR/Flk-1 VEGFR3/Flt-4

Biological Activity
Protocol
Purity & Documentation
References
Customer Review

Description

ZK-261991 is an orally active VEGFR tyrosine kinase inhibitor with an IC₅₀ of 5 nM for VEGFR2.

IC₅₀ & Target^[1]

VEGFR2

5 nM (IC₅₀)

In Vitro

ZK-261991 inhibits cellular receptor autophosphorylation in KDR-PAECs with an IC₅₀ of 2 nM. ZK991 inhibits VEGFR-3 autophosphorylation concentration dependently with an IC₅₀ of 20 nM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

ZK991 results in a significantly reduced recruitment of CD11b⁺ and LYVE-1⁺ cells into the murine cornea. ZK991 significantly improves the graft survival rate after corneal transplantation^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

443.50

Formula

C₂₄H₂₅N₇O₂

CAS No.

886563-25-3

SMILES

O=C(NC1=CC2=NN(C)C=C2C=C1)C3=CC=CC=C3NCC4=CC(NC(N(C)C)=O)=NC=C4

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. Deniz Hos, et al. Inflammatory Corneal (Lymph)angiogenesis Is Blocked by VEGFR-Tyrosine Kinase Inhibitor ZK 261991, Resulting in Improved Graft Survival after Corneal Transplantation. Investigative Ophthalmology & Visual Science May 2008, Vol.49, 1836-184

Cell Assay ^[1]	HLMVECs are cultured in EGM 2-MV medium. For the cytotoxicity assay, cells are seeded in 96-well plates in EGM 2-MV medium at a density of 5×10³ cells/well. Medium is changed every second day, and cells are cultured until reaching confluence. Then the medium is replaced with serum-free medium containing a tyrosine kinase inhibitor (PTK/ZK or ZK991; concentration 20 nM) and left overnight. Control cells receive the substance vehicle. The next day, cytotoxicity assay (WST-1 based) is performed according to the manufacturer's instructions. Colorimetric analysis is performed with an ELISA reader. Subsequent statistical analysis is performed, and graphs are drawn. The number of wells per group is as follows: PTK/ZK control group, n = 30; PTK/ZK 20 nM, n = 30; ZK991 control group, n = 30; ZK991 20 nM, n = 30. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[1]	Before corneal neovascularization, each animal is deeply anesthetized. Three 11-0 nylon sutures are placed intrastromally with two stromal incursions extending over 120°C of corneal circumference each. The outer point of suture placement is chosen near the limbus, and the inner suture point is chosen near the corneal center equidistant from the limbus to obtain standardized angiogenic responses. Sutures are left in place for 14 days. The first treatment group receive the tyrosine kinase inhibitor PTK/ZK (75 mg/kg, orally, twice daily), the second treatment group receive the tyrosine kinase inhibitor ZK991 (50 mg/kg, orally, twice daily), and control mice receive equal amounts of the substance vehicle. After 2 weeks, mice are killed and corneas are prepared. The corneal neovascularization assay includes 22 mice in the control group, 11 mice in the PTK/ZK treatment group, and 11 mice in the ZK991 treatment group. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
References	[1]. Deniz Hos, et al. Inflammatory Corneal (Lymph)angiogenesis Is Blocked by VEGFR-Tyrosine Kinase Inhibitor ZK 261991, Resulting in Improved Graft Survival after Corneal Transplantation. Investigative Ophthalmology & Visual Science May 2008, Vol.49, 1836-184

ZK-261991 Related Classifications

Inflammation/Immunology

Molarity Calculator
Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass		Concentration		Volume		Molecular Weight *
	=		×		×

The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)	×	Volume _(start)	=	Concentration _(final)	×	Volume _(final)
	×		=		×
C1		V1		C2		V2

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

ZK-261991886563-25-3ZK261991ZK 261991VEGFRVascular endothelial growth factor receptorInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Salutation

Applicant Name *

Email Address *

Phone Number *

Organization Name *

Department *

Requested quantity *

Country or Region *

Remarks